who would bet against that??
The Street Inside
rGilead Sciences (GILD) Price Target Raised to $115 at RBC Capital
Article Stock Quotes (1) Comments (0)
RBC Capital maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD) and raised its price taget to $115.00 (from $102.00). Analyst Michael J. Yee is positive on its next-gen HIV pill, with Phase II on tap next month
get in from the bottom- this has it all. Great Co- great drug-great data-great revenue and cash flow.
Sentiment: Strong Buy
this is cheap and government pushing China EV's.
they will load up
investors look to capitalize on a potential gold mine
Intercept has worldwide rights to Obeticholic acid (OCA), which is a multibillion dollar drug if it successfully completes Phase 3 trials for treating Nonalcoholic Steatohepatitis (NASH), for currently there is no treatment for the disease. The total market for a treatment of NASH is estimated to be over $30 billion.
Tesla powered higher by expansion plans
By Eric Platt in New York
Tesla to ship 100,000 vehicles in 2016, two-thirds ahead of its prior forecast.
Barron's Can Google It
Barron's "China makes life difficult for non-Chinese companies to do business like TSLA" China Wants KNDI "
China Wants China Made Cars. Beijing said it would start building charging stations that wouldn’t be compatible with $TSLA's technology.
19's Seems Pretty Undervalued To Me For Largest Electric Car Manufacture In Largest Populated Country in The World, China.
Last 2 Qts Knocked it out Of The Park, China Pushing EV's More Now. With Good ER Will See $25+